Bristol Myers Squibb (CGT Mfg) vs City of Hope (T Cell Manufacturing): CDMO Comparison
How does Bristol Myers Squibb (CGT Mfg) compare to City of Hope (T Cell Manufacturing)?
As of Mar 2026, Bristol Myers Squibb (CGT Mfg): 8 FDA inspections (including 4 NAI, 4 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 87. City of Hope (T Cell Manufacturing): 3 FDA inspections (including 2 NAI, 1 VAI and 0 OAI). Signal Score 84. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and City of Hope (T Cell Manufacturing) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (8 vs 3) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificates; City of Hope (T Cell Manufacturing) does not appear in EudraGMDP.
- Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; City of Hope (T Cell Manufacturing) does not.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (586 vs 215) — a broader sponsor book.
Across the cross-modality scorecard, Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs City of Hope (T Cell Manufacturing)
How does Bristol Myers Squibb (CGT Mfg) compare to City of Hope (T Cell Manufacturing)?
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg) is 87/100 and City of Hope (T Cell Manufacturing) is 84/100; Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record vs 3 for City of Hope (T Cell Manufacturing); European coverage is 2 active EMA+MHRA certificates for Bristol Myers Squibb (CGT Mfg) vs 0 for City of Hope (T Cell Manufacturing). Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or City of Hope (T Cell Manufacturing)?
Both Bristol Myers Squibb (CGT Mfg) and City of Hope (T Cell Manufacturing) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record; City of Hope (T Cell Manufacturing) has 3.
How do Bristol Myers Squibb (CGT Mfg) and City of Hope (T Cell Manufacturing) compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. City of Hope (T Cell Manufacturing) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or City of Hope (T Cell Manufacturing)?
Bristol Myers Squibb (CGT Mfg) is matched to 586 ClinicalTrials.gov records as a manufacturing partner; City of Hope (T Cell Manufacturing) is matched to 215. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 87/100 and City of Hope (T Cell Manufacturing) carries 84/100 — essentially tied for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →